Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
yahoo.com
news
2022-10-19 06:00:00

Nucleome Therapeutics

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines

Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises

Nucleome's pioneering platform seeks to identify direct genetic linkages to disease-associated genes for drug discovery

Funds will advance Nucleome's autoimmune disease programmes and fuel expansion of its dark genome atlas





Oxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome' or ‘the Company'), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.
